Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Further evolution toward effective therapy for acute ischemic stroke

M Fisher1, J Bogousslavsky

  • 1Department of Neurology, Memorial Health Care, University of Massachusetts Medical School, Worcester 01605, USA. fisherm@memorialhc.org

JAMA
|May 2, 1998
PubMed
Summary

Effective acute ischemic stroke treatment is advancing. Tissue-type plasminogen activator is approved within 3 hours, while neuroprotective drugs show promise for future combination therapies to maximize recovery.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Between neurology and psychiatry: The lively history of right hemisphere syndromes.

Revue neurologique·2023
Same author

Tabes dorsalis in the 19<sup>th</sup> century. The golden age of progressive locomotor ataxia.

Revue neurologique·2021
Same author

The medical itineraries of Blaise Cendrars. Neuropsychiatry marks life and literature.

Revue neurologique·2017
Same author

Smoothly progressive cerebral infarction over three weeks: Clinicopathological study in a patient with carotid occlusion.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Natural history of patients with chronic occlusion of the internal carotid artery.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2015
Same author

Treatment of acute stroke.

European journal of neurology·2013

Area of Science:

  • Neurology
  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Acute ischemic stroke treatment is a critical medical goal with ongoing advancements.
  • Thrombolytic therapy has emerged as a key treatment strategy for specific stroke patients.

Purpose of the Study:

  • To review the current landscape of acute ischemic stroke treatments.
  • To discuss the efficacy and limitations of existing therapies and future directions.

Main Methods:

  • Review of recent clinical trials and therapeutic approvals for acute ischemic stroke.
  • Analysis of the effectiveness and safety profiles of thrombolytic agents and neuroprotective interventions.

Main Results:

  • Tissue-type plasminogen activator (tPA) is approved for acute ischemic stroke within 3 hours of onset.

Related Experiment Videos

  • Streptokinase is not effective and increases hemorrhage risk; its early use was not evaluated.
  • Neuroprotective agents effective in animal models have not yet proven successful in human trials.

    • Conclusions:

    • Future acute ischemic stroke treatment may involve combination therapy with thrombolytics and neuroprotectives.
    • Careful patient selection and treatment timing are crucial for maximizing recovery potential with combination therapies.